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Abstract 
 
A family of cyclometalated Au(III) complexes featuring a tridentate C^N^C scaffold has been 
synthesized and characterized. Microwave assisted synthesis of the ligands has also been 
exploited and optimized. The biological properties of the thus formed compounds have been 
studied in cancer cells and demonstrate generally moderate antiproliferative effects. Initial 
mechanistic insights have also been gained on the gold complex [Au(C^N^C)(GluS)] (3), and 
support the idea that the thioredoxin system may be a target for this family of compounds 
together with other relevant intracellular thiol-containing molecules. 
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Introduction 
 
Gold-based organometallic complexes as anti-cancer agents have become increasingly popular 
in recent years, and several reviews have been published highlighting their structural diversity 
and biological activity.1 In fact, organometallic complexes display numerous attractive features. 
For example, while the organic ligand allows for the introduction of stereospecificity and 
alteration of the physicochemical properties by choosing different functional groups, the metal–
carbon (M–C) bond provides strong trans influence and, in the case of -bonded aromatic arene 
and cyclopentadienyl ligands, can act both as electron donors and acceptors. Furthermore, 
variations of the organic moiety are accessible, allowing the “fine-tuning” of the physiochemical 
properties of the respective metal compound. Finally, by choosing specific targeting moieties, 
either incorporation into the ligand or tethering to the metal centre can be achieved in a modular 
approach.  
Typical classes of organometallics include metallocenes, metallo-arenes, metallo-carbonyls, 
metallo-carbenes (e.g. N-heterocyclic carbenes, NHC), alkynyl complexes, etc.2 featuring both 
mononuclear and multinuclear scaffolds. All these compound families have been extensively 
applied in catalysis during the last decades.3 However, their medicinal use has been considered 
only much more recently.1c, 2, 4 
Concerning Au(I) organometallics, in 2008 Berners-Price et al. synthesized a series of 
mononuclear cationic Au(I) biscarbene complexes that show remarkable cytotoxicity in vitro 
and are able to induce mitochondrial damage5. Since then, the effects of Au(I) NHC complexes 
on cell metabolism and their interference with pathways relevant to cancer cell proliferation have 
been studied in a broad number of cases.1a, 4b, 6 
In this context, to explore the design of Au(III) compounds for biological applications, 
cyclometalation is a convenient method to stabilize the otherwise easily reduced Au(III) centre, 
and numerous cyclometalated scaffolds have been synthesized, including C^N, C^N^C, C^N^N 
and C^N^S.1b, 1c, 7 Cyclometalated Au(III) C^N compounds of general formula [(Au(damp)X2] 
(Fig. 1) with anticancer properties were first investigated by Parish, Buckley et al. in 1996,8 
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featuring a 2[dimethylamino)methyl]-phenyl (damp) backbone. The compounds display 
cytotoxic activity which is comparable to that of cisplatin, against a variety cancer cell lines. 
This activity is also accompanied by high selectivity and cytotoxicity in vitro which translates 
to moderate activity in vivo.  
 In 1996, the synthesis of an Au(III) 2-benzylpyridine derivative [Au(pyb-H)Cl2] (pyb-H 
= C^N cyclometalated 2-benzylpyridine) (Fig. 1) was reported by Cinellu et al. 9 In 2015 Casini, 
Cinellu et al. synthesized a structural analogue of this complex replacing the chlorido ligand, 
trans to the nitrogen atom, with 1,3,5-triazaphosphaadamantane (PTA).10 The resulting 
compound displays good cytotoxic activity against various cancer cell lines such as A2780 
(human ovarian adenocarcinoma). Furthermore, dinuclear oxo-bridged Au(III) C^N^N 
complexes of formula [(C^N^N)2Au2(µ-O)](PF6)2 (with C^N^N = 6-(1-methylbenzyl)-2,2‘-
bipyridine or 6-(1,1-dimethylbenzyl)-2,2’-bipyridine) showing moderate cytotoxicity against 
various cancer cell lines were synthesized.11 (Fig. 1).  
The field of Au(III) C^N^C complexes with anticancer properties has been closely examined by 
Che and co-workers1b, 12 For example, dinuclear complexes of the type [Aum(C^N^C)mL]n+ (with 
HC^N^CH=2,6-diphenylpyridine; m =1–3; n=0–3) showed higher cytotoxic activity against 
various cancer cell lines than their mononuclear counterparts. 12  
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Fig. 1. Representative cyclometalated Au(III) complexes with anticancer properties. 
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The highest cytotoxicities were observed for complex [Au2(C^N^C)2(-dppp)](OTf)2 ( 
Fig. 1), relating to the cytotoxicity of the free 1,2-bis(diphenylphosphino)propane (dppp) ligand. By 
replacing the phosphane moiety with an NHC ligand as in the cationic C^N^C stabilized complexes 
[Aun(R–C^N^C)n(NHC)]n+, a general decrease in cytotoxic effects has been noted,13 supporting the idea 
that indeed phosphine ligand-mediated cytotoxicity plays a major role in the overall anticancer 
properties. Nevertheless, within this series, the mononuclear complex [Au(C^N^C)(IMe)]CF3SO3 
(IMe = 1,3-dimethylimidazol-2-ylidene) (Fig. 1) shows higher cytotoxic activity than its dinuclear 
analogue, and a high degree of selectivity towards human cancer cells compared to normal lung 
fibroblasts (CCD-19Lu). Through DNA interaction studies it was demonstrated that the compound 
induces DNA strand breaks and can cause subsequent cell death through the stabilization of 
Topoisomerase-linked DNA14. Treatment of nude mice bearing PLC tumors (hepatocellular carcinoma) 
with [Au(C^N^C)(IMe)]CF3SO3 at 10 mg/kg/week for 28 days significantly suppressed (47%) tumor 
growth when compared with that of the vehicle control.13 
Of note from the same group, is the application of supramolecular polymers, self-assembled 
from cyclometalated Au(III) C^N^C complexes, as anticancer agents. The mononuclear 
complex [Au(C^N^C)(4-dpt)]+ (C^N^C =2,6-diphenylpyridine, 4-dpt = 2,4-diamino-6-(4-
pyridyl)-1,3,5-triazine) (Fig. 1) was chosen due to the ability of the antiangiogenic 4-dpt ligand 
to form intramolecular hydrogen bonds and to establish π-π interactions, leading to 
supramolecular complex formation by self-assembly at ambient temperatures.15 The 
supramolecular polymer displays high cytotoxic activity towards B16 cells (murine cancer).  
In terms of possible mechanisms of action, cytotoxic Au(III) complexes can interact with protein 
targets16, including those constituting the thioredoxin system, often overexpressed in tumor cells 
and involved in maintaining the intracellular redox balance17. Among the enzymes included in 
this system, the seleno-protein thioredoxin reductase (TrxR) contains a cysteine-selenocysteine 
redox pair at the C-terminal active site, and the solvent-accessible selenolate group, arising from 
enzymatic reduction, constitutes a likely target for “soft” metal ions such as gold. In addition, 
Au(III) complexes can interfere with thiols including glutathione, the most abundant intracellular 
reducing agent.  
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Within the scope of new medicinally relevant organometallic Au(III) compounds, two new 
cyclometalated Au(III) complexes of the general formula [Au(III)(C^N^C)X] (with C^N^C = 
2,6-diphenylpyridine and X = Cl, thio-β-D-glucose-tetraacetate (GluS), 1,3,5-
triazaphosphaadamantane (PTA)) were synthesized. The complexes were prepared starting from 
the literature known chlorido precursor [Au(III)(C^N^C)Cl]18 (Fig. 2, 1), substituting the 
chlorido ligand with PTA (2) and thio-β-D-glucose-tetraacetate (GluSH) (3), respectively. The 
PTA ligand was chosen to increase the water solubility, while the GluS− ligand was selected as 
modulator of the hydrophilic/lipophilic character, as well as a possible facilitator of the 
compound’s uptake via interactions with the GLUT1 transporter. A second series of analogous 
C^N^C complexes - Au(III)[(C^NR^C)] - was synthesized starting from the corresponding 2,4,6-
triarylpyridine ligands, but featuring different substituents in the para position of the 
phenylpyridine (R = OH, F, Br, NO2) (Fig. 2, 4-7). Notably, complex 5 has already been 
described by Che et al. in 2013 as a precursor for photoactive functionalized bis-cyclometalated 
alkynyl gold(III) complexes suitable as phosphorescent organic light-emitting diodes 
(OLEDs).19 However, the authors did not evaluate the biological activity of this complex. All 
the cyclometalated Au(III) complexes reported herein were studied for their antiproliferative 
effects against different human cancer cell lines, including some that are resistant to cisplatin. 
Moreover, compounds 1-3 were also tested for their inhibition properties of TrxR on the purified 
protein and in cell lysates. The effects of the new complexes on the oxidation state of Trx were 
also investigated by Western blot analysis. Discrimination between the oxidation of the 
GSH/GSSG system and the Trx system can be very informative in terms of mechanisms of 
toxicity since different cellular pathways are controlled by GSH and Trx. Thus, estimation of the 
glutathione content was performed in treated cells.  
2. Results and Discussion 
 
2.1 Synthesis and structural characterization 
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To achieve the synthesis of the new compounds, the transmetalation pathway via the respective 
Hg(II) precursor was followed as described in Fig. 2.  Thus, treatment of 2,6-diphenylpyridine 
or para substituted 2,4,6-triarylpyridines with mercury(II) acetate, followed by salt metathesis 
with LiCl, affords the organomercury(II) precursors. Subsequent transmetalation with K[AuCl4] 
in refluxing acetonitrile, adapting previously reported procedures,20 yields the respective 
cyclometalated Au(III) complexes. The synthesis of the cyclometalated precursor 
[Au(C^N^C)Cl] (C^N^C= 2,6-diphenylpyridine) (1) has been reported in 1998 by Che et al.20a, 
but the biological activity of this complex has not been reported. Afterwards, two novel 
derivatives, namely the cationic [Au(C^N^C)(PTA)][PF6] (2) and the neutral 
[Au(C^N^C)(GluS)] (3), have been obtained from complex 1 by ligand exchange reactions (Fig. 
2) and characterized by means of NMR, ESI-MS and elemental analysis. 
Complex 2 contains the water-soluble ligand PTA, which, together with the positive charge of 
the resulting complex, should improve the overall water solubility while being non-cytotoxic per 
se. As has been reported before, replacement of a trans bound chlorido ligand by a tertiary 
phosphine at the Au(III) center can be achieved by first abstracting the halide to unveil a cationic 
gold (III) that can then be intercepted by the donor PTA ligand.10, 18  
 
 
 
 
 
 
 
 
 
Fig. 2. General synthesis scheme of the obtained cyclometalated Au(III) [C^N^C] complexes 1-3. 
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Thus, by reacting 1 with one equivalent of PTA in the presence of KPF6 in acetone for 3 h at 
room temperature, complex 2 is obtained in good yields. Single crystals of complex 2 suitable 
for X-ray diffraction were grown by slow diffusion of n-pentane into an acetone solution of the 
compound. The crystallographic structure of 2 is depicted in Fig. 3. The Au(III) centre is 
coordinated in a slightly distorted square planar fashion by the C^N^C pincer ligand and PTA 
with bond lengths of Au1—C1 = 2.106(3) Å, Au1—N1 = 2.025(2) Å, Au1—C17 = 2.091(3) Å 
and Au1—P1 = 2.2707(7) Å which are comparable to literature-reported values for the Au(III)-
C^N^C19 scaffold and an Au(III) ion binding to PTA.10, 21 While there is no significant out-of-
plane distortion of the square planar arrangement, the geometry of the pincer ligand causes an 
in-plane distortion illustrated by the C1—Au1—C17 angle of 160.8(1)°. The pincer ligand itself 
is close to perfect planarity with only the phenyl-side-arm containing C17 slightly being bent 
out of plane and the C1-C6 phenyl ring being bent even more slightly in the antipodal direction. 
Fig. S1 in the supplementary material depicts the allocation of the signals for 1H and 13C NMR 
spectra of the complexes. When comparing the free 2,6-diphenylpyridine ligand to the obtained 
complexes 1-3, a significant shift in the 1H NMR spectrum for Hf can be observed (see Fig. S1 
in the supplementary material for the allocation of the signals for 1H and 13C NMR spectra of the 
complexes), resulting from the strong de-shielding caused by the –I effect of the electron-
accepting Au-Cl moiety (Δδ =0.48 ppm for complex 1).  
 
 
Fig. 3. ORTEP style presentation of the molecular structure of compound 2 in the solid state with ellipsoids given at 50% 
probability level. Hydrogen atoms, hexafluorophosphate anions and co-crystallized water molecules are omitted for clarity. 
Selected bond lengths (Å) and angles (°): Au1—C1 2.106(3), Au1—N1 2.025(2), Au1—C17 2.091(3), Au1—P1 2.2707(7), 
P1—Au1—C1 97.13(7), P1—Au1—C17 102.10(7), N1—Au1—C1 80.32(9), N1—Au1—C17 80.44(9). 
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Complex 1 was also treated with one equivalent of thio-β-D-glucose tetraacetate (GluSH) and 
sodium carbonate in dichloromethane for 1.5 hours at room temperature to obtain compound 3 
in good yields. As this ligand is optically active, the 1H NMR presents less sharp signals than 
the spectrum for complex 2. The proton count, however, fits the structure of 3 perfectly and the 
signal of the thiol proton at 2.20 ppm is not present in the product NMR spectrum, confirming 
the bond formation between gold and sulfur, while the four acetate groups of the GluS- ligand 
appear as sharp singlet signals between 1.96 and 1.77 ppm. Moreover, all protons of the GluS - 
are shifted as well, resulting from the strong de-shielding caused by the –I effect of the electron-
accepting Au(III) centre. The structure of complex 3 was further assessed by ESI-MS and 
elemental analysis. 
Microwave assisted synthesis can afford several benefits, especially to modular synthesis 
programmes such as those concerning medicinal chemistry. Such benefits may come in the form 
of increased product purity and reduced reaction times.22 The use of robotic handlers and touch-
screen interfaces can greatly streamline the preparation of a library of compounds, especially 
when using an Initiator Robot system. Thus, the para-substituted 2,4,6-triaryl [C^NR^C] ligands 
(L4-7) for complexes 4-7 (Fig. 4) were obtained by applying microwave assisted ligand 
synthesis. In detail, microwave irradiated synthesis of the [C^NR^C] ligands was carried out 
adapting a previously reported procedure for hydroxylated tri-substituted pyridines.23 
Optimization of the reaction conditions was performed with respect to temperature, power and 
reaction time of the irradiation. A major benefit of the microwave synthesis is the circumvention 
of otherwise needed catalyst, such as previously reported Bi(OTf)3,24 and solvents, thus enabling 
a metal and solvent free synthesis. 
A previously described procedure reports on the use of a conventional microwave with 
unfocused irradiation at 400 Watts.23 We found this high power in our focussed reactor to cause 
pressure build up within in the system, leading to the termination of the microwave through 
triggering of the inbuilt safety features. A basis set (100 W, 120 °C, 30 minutes) was chosen, 
from which on the single parameters were optimized. The irradiation power has been altered as 
shown in Table S1 in the supplementary material, with the other parameters being fixed at basic 
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conditions. The maximum product yield was found for a power of 175 W. The yield performance 
drops significantly after the power exceeds 200 W, which is believed to be contributed to 
beginning decomposition of the formed triarylpyridines. 
The next parameter that could be altered is the temperature as depicted in Table S2 in the 
supplementary material. The maximum product yield was found for a temperature of 180 °C, 
while yield performance dropped significantly after the temperature exceeds 200 °C. The 
reaction time was the last parameter of the basis set to be altered as can be seen in Table S3. As 
expected, the yield reaches a plateau after a defined period of time (80 min and upwards). 
Overall, the combined optimized parameters for the microwave irradiated synthesis of the 2,4,6-
triarylpyridine ligands were found to be at 180 °C, 175 W and 80 minutes.  
Following the successful development of a microwave protocol for the preparation of the 
ligands, the cyclometalated Au(III) complexes were obtained via transmetalation of the 
respective [Hg(C^NR^C)Cl] precursors with K[AuCl4]. This was achieved by heating the 
reaction mixture to reflux in acetonitrile for 24 hours (Fig. 4). Likewise, to the 2,6-
diphenylpyridine systems, a significant shift in the 1H NMR spectrum for H1 can be observed 
when comparing the free 2,4,6-triaryl ligands to their respective complexes 4-7, resulting from 
the strong de-shielding caused by the –I effect of the electron-accepting Au-Cl moiety (Δδ =0.3λ 
ppm for complex 4).  
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Fig. 4. Synthesis of [Au(III)(C^NR^C)] (C^NR^C = para-substituted 2,4,6-triarylpyridine) complexes. 
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visible spectral changes over a 24 h period at room temperature (Figure S25). 
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moderate effects. The highest antiproliferative effects are found for complexes 1 and 3 in 2008 
cells, with IC50 values of 29 M ± 3 and 7.0 M ± 1.2, respectively. 
 
Table 1. IC50 values (ȝM) of the Au(III) compounds 1-7, ligands (L4-L7) and cisplatin against A549 and SKOV-3 
(72 h incubation) and 2008 (48 h incubation). 
compound A549 SKOV-3 2008 
1 35 ± 5 39 ± 7 29 ± 3 
2  50 48.1 ± 2.3  50 
3 30.4 ± 1.3 13.0 ± 0.9 7.0 ± 1.2 
4  50  50 - 
5  50  50 - 
6  50  50 - 
7  50  50 - 
L4 30.0 ± 4.7 28.8 ± 5.5 - 
L5 42.3 ± 5.3 44.5 ± 7.9 - 
L6 30.8 ± 4.5 59.5 ± 9.7 - 
L7 >100 >100 - 
cisplatin 12 ± 0.5 16.3 ± 1.7 - 
 
 
2.3 Thioredoxin reductase inhibition 
 
Since TrxR is also a potential target for gold complexes, in vitro inhibition of purified rat liver 
cytosolic and mitochondrial TrxR by compounds 1-3 was studied and compared with the activity 
of auranofin, a well-known TrxR inhibitor, using established protocols as described in the 
Experimental section. The results are summarized in Table 2. All compounds are good inhibitors 
of cytosolic thioredoxin reductases (TrxR1), showing IC50 values in the nanomolar range of 
concentrations, with complex 3 being the most potent. Conversely, the mitochondrial isoform of 
the enzyme is slightly inhibited by the three complexes after incubation in the same experimental 
conditions, revealing a different inhibitory capacity on the two isoforms. Further studies 
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demonstrated that 3 is also able to inhibit the TrxR closely related, but selenium-free, enzyme 
glutathione reductase (GR) although 60-fold less efficiently than in the case of TrxR (Table 2). 
 
Table 2. IC50 values of the inhibition of TrxR1, TrxR2 and GR on the isolated enzymes. 
 IC50 (nM) 
Complex TrxR1 TrxR2 GR 
auranofin 0.9 ± 0.3 3 ± 1 >10 000 
1 10 ± 1 59 ± 5 219 ± 18 
2 10 ± 1 213± 20 439 ± 7 
3 3± 1 60 ± 4 180 ± 22 
 
The effect of compounds 1-3 on TrxR and GR activities was also evaluated in cell lysates. For 
this purpose, 2008 cells, where the three compounds showed markedly different cytotoxic 
effects, were pre-treated for 48 h with 1-3 at different concentrations (Fig. 5A). Complex 3 was 
the most effective in inhibiting TrxR, followed by compound 2. Complex 1 was scarcely active. 
In addition, GR activity was also determined and, as shown in Fig. 5B, the enzyme was not 
inhibited by the compounds even at 50 µM concentration. 
 
 
 
Fig. 5. Thioredoxin reductase and glutathione reductase (insert) activities in 2008 ovarian cancer cells after 48 h treatment with 
1-3. For TrxR activity determinations, cells (1 x 106) were treated with the compounds at the indicated concentration between 
0-40 µM. GR activity was evaluated after cells treatment with 50 µM of each of the three compounds, as reported in the 
Experimental section. 
 
2.4 Effects on cellular redox state 
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Furthermore, the cellular redox state was evaluated after the incubation of 2008 cells with 1-3. 
For the determination of the total thiols in cell lysates, an assay was conducted according to the 
protocol described in the Experimental section. The results presented in Fig. 6 show that the total 
amount of thiols is unaltered upon treatment with 1 and 2, indicating that these complexes have 
no effect on the redox state of the intracellular sulfhydryl groups, while at 50 ȝM, 3 shows a 
decrease of about 40% of the total thiols. This suggests that 3 determines a redox imbalance 
interacting with thiols inside the cells.  
Since the glutathione redox pair (GSH/GSSG) is another fundamental component of the cell 
redox regulation, an analysis of the total glutathione content and of the GSH/GSSG ratio was 
performed in 2008 cells, after treatment with 1-3 for 48 hours. The obtained results are elucidated 
in Fig. 6B. After the treatment of 5 x 105 ovarian cancer cells, an important increase of oxidized 
glutathione, suggesting thiols oxidation, can be observed only in the presence of 3 (50 µM), 
while 1 and 2 do not affect the glutathione system since total and oxidized levels were 
comparable to the control cells (Fig. 6B). 
Therefore, the redox state of Trx1 and Trx2 in 2008 cells treated for 48 h with 1 and 3 was 
studied (Fig. S26, supplementary material) to confirm that the inhibition of TrxR determines an 
increase of oxidation of the principal substrates. Interestingly, complex 3 induces a marked 
oxidation of Trx1 and Trx2, evidenced by the shift of the bands relative to the two proteins 
towards their oxidized form by western-blot analysis, providing indirect evidence that TrxR is a 
pivotal target of this compound in cells. 
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Fig. 6. Total thiols: (A) in 2008 ovarian cancer cells after the treatment with 1-3. A: cells (5 x 105) were treated with the 
compounds at the indicated concentrations and then subjected to total thiol determination (light bars: 25 µM; dark bars: 50 
µM). (B) Glutathione redox state ratio (GSSG/GSH) after cell treatment with 50 µM of the three compounds. 
 
3. Conclusions 
 
Two new Au(III)[C^N^C] complexes, [Au(C^N^C)(PTA)][PF6] (2) and [Au(C^N^C)(GluS)] 
(3), and three new Au(III)[C^N(R)^C] complexes with R= Ph-p-OH (4), Ph-p-Br
 
(6), Ph-p-NO2 
(7) have been synthesized. Microwave assisted ligand synthesis for the para substituted 2,4,6-
triaryl ligands for complex 4-7 was optimized concerning applied temperature, power and 
reaction time. The compounds have been examined for their antiproliferative effects in a small 
panel of human cancer cells. In general, the compounds are poorly toxic, with the exception of 
compounds 1 and 3, which were active in the 2008 ovarian cancer cells. Initial mechanistic 
studies have shown that 1-3 are nanomolar inhibitors of isolated cytosolic and mitochondrial 
TrxRs, while they scarcely affect the activity of GR, supporting the idea that they could bind 
preferentially TrxRs. These results are confirmed also by the increase of the oxidized form of 
Trxs, upon metallodrugs’ treatment. Furthermore, the observed effects on the overall redox state 
A 
B 
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of the cells of complex 3 suggest that this derivative is particularly effective in disrupting the 
thiol redox homeostasis of the cell.  
Overall, the obtained results demonstrate that the reported Au(III) complexes need to be further 
optimized for biological applications, especially in terms of solubility and potency on cancer 
cells. Moreover, a central role of the ancillary ligands in the observed anticancer effects has been 
highlighted, in line with previous studies by Che et al. Nevertheless, these initial results provide 
some indications on the possible cellular targets for this family of compounds.  
In terms of possible derivatization of the organometallic scaffold, Au(C^N^C) systems replacing 
the central pyridine ring with a pyrazine have been reported recently.25 As they display intense 
thermally activated delayed fluorescence (TADF), these Au(C^N^C) complexes could lead to a 
convenient way to monitor the uptake of anticancer compounds via fluorescence microscopy. 
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4. Experimental Section 
 
4.1 General remarks 
 
Reactions were carried out under purified argon using standard Schlenk techniques. Solvents 
were dried, degassed and stored over molecular sieve and under argon before use. Microwave 
reactions were carried out in a CEM Focused Microwave™ Synthesis System or a Biotage® 
Initiator Robot Eight and Sixty. All physico-chemical analytics were performed at the 
Technische Universität München and the University of Cardiff. UV−vis spectra were recorded 
on a Perkin-Elmer Lambda 650 UV/vis spectrophotometer. Electrospray ionization mass spectra 
(ESI-MS) were obtained on a High-Resolution Waters LCT TOF Bruker HR-QTOF maXisPlus 
operating in positive ionization mode. The samples were dissolved in 1 ml of the appropriate 
solvent and 10 µl were injected directly in to the mass spectrometer. The mass range was scanned 
between 100 and 2000 and Leucine Enkephalin was used as an online calibrant. NMR spectra 
were recorded on a Bruker Avance DPX-300, 400 or 500 at 298 K. All deuterated solvents were 
purchased from Deutero GmbH and Sigma Aldrich. Chemical shifts are given in δ (ppm) and 
refer to the residual 1H and 13C(1H) signals of the respective solvent. In allocating the signals the 
following abbreviations have been used: s- singlet, d- doublet, t -triplet, q-quartet, m- multiplet. 
Coupling constants J are given in Hz. X-ray intensity data were measured on a Bruker D8 
Venture Duo IMS system equipped with a Helios optic monochromator and a Mo IMS 
microsource (Ȝ=0.71073 Å). All mercury precursors were prepared according to Constable  et 
al.20b. The commercially available ligand 2,6-diphenylpyridine (CAS 3558-69-8) and Au(III) 
precursor K[AuCl4] (98%, CAS 13682-61-6) were purchased from Sigma-Aldrich and utilized 
without further purification. Crystallographic Details are reported in the Supporting Information. 
 
4.2 Synthesis of [Au(III)(C^N^C)]n+ (C^N^C= 2,6-diphenylpyridine) complexes 
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[Au(C^N^C)Cl] (1). Preparation was carried out with slight changes to the synthesis by Che et 
al.20a 
Hg(C^N^CH)Cl (1eq, 0.51 g, 1.09 mmol) and K[AuCl4] (1eq, 0.41 g, 1.09 mmol) are refluxed 
in acetonitrile (20 mL) under argon for 24 h at 80°C forming a greenish precipitate. The crude 
solid is filtered, washed with diethyl ether and n-pentane and dried under reduced pressure to 
afford an electrostatic light-yellow, solid (0.18 g, 0.39 mmol, 36% yield). 13C NMR spectra have 
not been reported in the literature so far. 
1H NMR (400 MHz, DMSO-d6) δ 8.1λ (t, J = 8.0 Hz, 1H, Ha), 7.98 (d, J = 8.1 Hz, 2H,Hf), 
7.88(d, J = 7.7 Hz, 2H, Hc), 7.69 (d, J = 7.2 Hz, 2H,Hb), 7.43 (t, J = 7.3 Hz, 2H, Hd), 7.32 (t, J = 
7.6 Hz, 2H, He). 13C(1H) NMR (101 MHz, DMSO) δ 16λ.5 (C-N), 164.1 (C-C), 148.4 (C-Ha), 
142.3 (C-Au), 133.0 (C-Hc), 131.7 (C.He), 127.6 (C-Hd), 126.1 (C-Hf), 118.6 (C-Hb). Positive 
ESI-MS (acetone): m/z = 462.21 [M+H]+ (calcd for C17H12AuClN: 462.03). Anal. Calc. for 
C17H11AuClN: C, 44.22; H, 2.40; N, 3.03 %. Found: C, 44.16; H, 2.18 ; N, 3.23 % 
[Au(C^N^C)(PTA)][PF6] (2). Complex 1 (1 eq., 100 mg, 0.22 mmol) is added to KPF6 (5 eq., 
202.47 mg, 1.10 mmol) in acetone (25 mL). PTA (1 eq., 34.57 mg, 0.22 mmol) is added to the 
suspension at room temperature under vigorous stirring. The reaction is stirred at room 
temperature for 3 hours. Acetone is subsequently partly removed, dichloromethane was added 
and the solution was filtered through Celite®. The volatiles are removed under reduced pressure 
and the resulting white solid is washed with ice-cold acetone, n-pentane and diethylether (114.7 
mg, 0.16 mmol, 73% yield). 
1H NMR (400 MHz, Acetone-d6) δ 8.28 (t, J = 8.0 Hz, 1H, Ha), 8.01 (m, J = 8.5 Hz, 6H, Hb,c,f), 
7.56 (t, J = 7.5 Hz, 2H, Hd), 7.46 (t, J = 7.5 Hz, 2H, He), 5.21 (d, J = 2.1 Hz, 6H, N-CH2), 4.99 
(d, J = 13.1 Hz, 3H, P-CHaHb), 4.80 (d, J = 13.3 Hz, 3H, P-CHaHb). 13C NMR (101 MHz, 
Acetone-d6) δ 16λ.5 (C-N), 164.7 (C-C), 151.4 (C-Ha), 146.4 (C-Au), 137.6 (C-Hc), 133.5 (C-
He), 129.1 (C-Hd), 128.0 (C-Hf), 119.6 (C-Hb), 73.1 (N-CH2), 51.3 (P-CH2). Positive ESI-MS 
(acetone): m/z = 583.110 [M]+ (calcd for C23H23AuN4P: 583.126). Anal. Calc. for 
C23H23AuF6N4P2: C, 37.93; H, 3.18; N, 7.69 %. Found: C, 37.79; H, 3.24; N, 7.38 %. 
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[Au(C^N^C)(GluS)] (3). Complex 1 (1 eq., 50 mg, 0.115 mmol), is added to thio-β-D-glucose 
tetraacetate (1 eq., 41.9 mg, 0.115 mmol) and Na2CO3 (5 eq., 61 mg, 0.575 mmol) in 
dichloromethane (20 mL). The suspension is stirred for 1.5 hours at room temperature. The 
solution is filtered through Celite® and concentrated under reduced pressure. Upon cooling and 
subsequent addition of pentane a light yellow precipitate is formed which is filtered, washed 
with diethylether and n-pentane and dried under reduced pressure (78.96 mg, 0.10 mmol, 87% 
yield). 
1H NMR (500 MHz, Acetone-d6) δ 8.34 –7.69 (m, 5H, Ha,b,c), 7.61 – 7.14 (m, 6H, Hd,e,f), 5.20 – 
5.10 (m, 2H, 2 CH), 4.98 (m, 1H, CH), 4.89 (t, J = 9.4 Hz, 1H, CH), 4.79 (t, J = 9.7 Hz, 1H, 
CH), 4.15 (dd, J = 12.3 Hz, 2.1 Hz, 1H, CH2-sugar), 4.02 (dd, J = 12.3 Hz, 5.6 Hz, 1H, CH2-
sugar), 1.96 (s, 3H, OAc), 1.94 (s, 3H, OAc), 1.86 (s, 3H, OAc), 1.77 (s, 3H, OAc). Positive 
ESI-MS (acetone): m/z = 790.1442 [M+H]+ (calcd for C31H31AuNO9S: 790.1385). Anal. Calc. 
for C31H30AuNO9S: C, 47.15; H 3.83; N, 1.77; S, 4.06 ;%. Found: C, 47.01; H, 3.68; N, 1.85; S, 
3.75 %. 
 
4.3 Synthesis of [Au(III)(C^NR^C)] (C^NR^C=substituted 2,4,6-triarylpyridine) complexes 
 
4.3.1 General procedure 
C^NR^C ligand synthesis (L1-L7): A mixture of the respective para-substituted benzaldehyde 
(1eq), acetophenone (2.0 eq) and ammonium acetate (6.0 eq) is subjected to microwave 
irradiation of 180 W at 175 °C for 80 minutes. The resulting biphasic reaction mixture is then 
transferred to a separating funnel, treated with equal volumes of ice-water and diethyl ether and 
shaken well. The aqueous phase containing excess ammonium acetate is extracted three times 
with diethyl ether. The organic phases are combined and concentrated under reduced pressure to 
afford the crude product. Recrystallization from ethanol and subsequent drying under reduced 
pressure delivers the respective C^N(R)^C ligand. Column chromatography over silica gel 
(hexane/ethyl acetate = 1.5/1) can be performed if required.  
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[Au(III)(C^NR^C)] complex synthesis: The respective Hg(C^NR^CH)Cl precursor (1eq, 100 
µmol) and K[AuCl4] (1eq, 100 µmol) are added to acetonitrile (20 mL) using standard Schlenk 
techniques. Under vigorous stirring the suspension is kept at 100°C for 48 h under reflux upon 
which solubilisation of the educts occurs. The solution is then allowed to cool to room 
temperature leading to the precipitation of a solid. The crude product is filtered and then washed 
with ice-cold diethyl ether and n-pentane. Any remaining solvent is removed under reduced 
pressure to afford the complexes as solids.  
[Au(III)(C^NOH^C)Cl] (4) The compound is obtained as a pale yellow solid (38,77  mg, 70 
µmol, 70% yield). 1H NMR (400 MHz, DMSO-d6) δ λ.76 (s, 1H, OH), 8.27 (d, J = 6.8 Hz, 4H, 
H1,4), 8.06 (d, J = 13.7 Hz, 4H,H6,7), 7.60 – 7.53 (m, 4H, H2,3), 7.51 – 7.46 (m, 2H,H5). 13C NMR 
(101 MHz, CDCl3) δ 157.5 (2 C-N), 151.2 (C-OH), 150.0 (Cpara-N), 140.1 (C-Au), 129.0, 128.9, 
128.8, 128.0, 127.3, 127.3, 126.2, 116.8, 116.2, 112.6. Positive ESI-MS (acetone/water): m/z = 
571.0382 [M+H2O]+ (calcd for C23H17AuClNO2: 571.0613). Anal. Calc. for C23H15AuClNO: C, 
49.88; H, 2.73; N, 2.53;%. Found: C, 49.63; H, 2.55; N, 2.57;%. 
[Au(III)(C^NF^C)Cl] (5) The compound is obtained as a pale yellow solid (35.01 mg, 63 µmol, 
63% yield). 1H NMR (300 MHz, DMSO-d6) δ 8.32 (s, 2H, H5), 8.25 (m, 2H, H7), 8.12 (d, J = 
7.7 Hz, 2H, H4), 7.70 (d, J = 7.2 Hz, 2H, H1), 7.54 – 7.41 (m, 4H, H2,3), 7.34 (m, 2H, H6). 13C 
NMR (101 MHz, DMSO) δ 18λ.1 (C-F), 142.7 (C-Au), 137.4 (2 C-N), 134.0 (Cpara-N), 133.3, 
131.9, 131.3, 130.9, 128.9, 128.6, 128.1, 124.1, 122.8. Positive ESI-MS (acetone): m/z = 
555.0463 [M]+ (calcd for C23H17AuClNO2: 555.0464). Anal. Calc. for C23H14AuClFN: C, 47.15; 
H 3.83; N, 1.77 %. Found: C, 47.04; H 3.68; N, 1.79 %. 
[Au(III)(C^NBr^C)Cl] (6) The compound is obtained as a pale yellow solid (40.08 mg, 65 
µmol, 65% yield). 1H NMR (300 MHz, DMSO-d6) δ 8.32 (s, 2H, H5), 8.12 (m, 4H, H4,1), 7.85 
(d, J = 6.0 Hz, 2H, H7), 7.71 (d, J = 8.0 Hz, 2H, H6), 7.50 – 7.41 (m, 2H, H2), 7.40 – 7.29 (m, 
2H, H3). 13C NMR (75 MHz, DMSO) δ 157.1 (2 C-N), 148.8 (Cpara-N), 139.1 (C-Au), 137.3, 
132.4, 130.0, 129.8, 129.2, 127.4 (C-Br), 124.4, 117.0. Positive ESI-MS (acetone): m/z = 
616.9659 [M]+ (calcd for C23H17AuClNO2: 614.9664). Anal. Calc. for C23H14AuBrClN: C, 
44.80; H, 2.29; N, 2.27 %. Found: C, 44.61; H, 2.24; N, 2.36 %. 
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[Au(III)(C^NNO2^C)Cl] (7) The compound is obtained as a pale yellow solid (35.55 mg, 61 
µmol, 61% yield). 1H NMR (400 MHz, DMSO-d6) δ 8.44 (s, 2H, H5), 8.32 (d, J = 8.6 Hz, 2H, 
H7), 8.23 (d, J = 8.7 Hz, 2H, H6), 7.87 – 7.74 (m, 4H, H1,4), 7.58 – 7.51 (m, 2H, H3), 7.50 – 7.40 
(m, 2H, H2). 13C NMR (75 MHz, DMSO) δ 157.2 (2 C-N), 148.3 (C-NO2), 147.8 (Cpara-N), 
144.6, 144.1, 138.9 (C-Au), 130.0, 129.9, 129.3, 129.2, 127.5, 124.5, 117.4. Positive ESI-MS 
(acetone): m/z = 582.0400 [M]+ (calcd for C23H17AuClNO2: 582.0409). Anal. Calc. for 
C23H14AuClN2O2: C, 47.40; H, 2.42; N, 4.81 %. Found: C, 47.34; H, 2.37; N, 4.83 %. 
 
4.4 Antiproliferative assays 
 
The human cancer cell lines A549 (lung adenocarcinoma) and SKOV-3 (ovarian 
adenocarcinoma) were cultured in DMEM containing GlutaMax-I supplemented with 10% FBS 
and 1% penicillin/streptomycin, at 37 °C in a humidified atmosphere of 95% of air and 5% CO2 
while 2008 ovarian cancer cells were grown in RPMI with 10% FBS and 1% 
penicillin/streptomycin in the same conditions. Cells in an exponential growth rate were seeded 
in 96-well plates) at a concentration of 8 x 103 cells/well, and grown for 24 h in complete 
medium. Solutions of the compounds were prepared by diluting a stock solution in DMSO (10 -
2
 M) of the corresponding compound in culture media (the percentage of DMSO in the culture 
medium never exceeded 0.5%). Cisplatin was dissolved in aqueous solution (10-3 M) to avoid 
ligand exchange reactions with DMSO. Subsequently, intermediate dilutions of the compounds 
were added to the wells to obtain a final concentration ranging from 0.5 to 100 ȝM. Following 
72 h (A549, SKOV-3) or 48 h (2008) drug exposure, medium was removed and 3 (4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in PBS/10mM glucose was 
added to the cells at a final concentration of 0.50 mg/mL and incubated for 2.5 h. Afterwards, 
the medium was removed and the violet formazan crystals dissolved in DMSO. The optical 
density of each treatment was quantified in quadruplicate at 540 nm, using a multi-well plate 
reader (ThermoMax microplate reader, Molecular devices, US), and the percentage of surviving 
cells was calculated from the ratio of absorbance between treated and untreated cells. The IC50 
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value was calculated as the concentration reducing the proliferation of the cells by 50% and is 
presented as a mean (± SD) of at least three independent experiments. 
 
4.5 Enzyme inhibition assays on isolated enzymes 
 
Highly purified aliquots of cytosolic and mitochondrial rat liver thioredoxin reductases26 27 were 
utilized. Thioredoxin reductases activity was determined in 0.2M NaKPi buffer, 5 mM EDTA, 
pH 7.4, by estimating the DTNB reduction in the presence of 0.25 mM NADPH after 5 min 
incubation with increasing concentration of 1-3. The reaction was started with 1 mM DTNB and 
followed spectrophotometrically at 412 nm for about 10 min at 25 °C. Yeast glutathione 
reductase activity was measured in 0.2 M Tris–HCl buffer (pH 8.1), 1 mM EDTA, and 0.25 mM 
NADPH, with the various compounds. The assay was initiated by addition of 1 mM GSSG and 
followed spectrophotometrically at 340 nm. 
 
4.6 Analysis of thioredoxin reductase and glutathione reductase activities in cell lysates 
 
2008 ovarian cancer cells, grown in completed RPMI medium, were treated in the presence of 
1-3 in various conditions. Briefly, 2008 cells (1 × 106) were incubated with increasing 
concentrations of the three compounds for 48 h. Then, cells were harvested, washed with PBS 
and lysed with a modified RIPA buffer: 150 mM NaCl, 50 mM Tris-HCl, 1 mM EDTA, 0.1% 
SDS, 0.5% DOC, 1 mM NaF, supplemented with an antiprotease cocktail (“Complete”Roche, 
Mannheim, Germany) and 0.1 mM PMSF. After 40 min of incubation at 4 °C, lysates were 
centrifuged at 14000g for 5 min and aliquots (50µg) of the supernatants were utilized for enzyme 
activities as described above.  
 
4.7 Total thiols estimation in 2008 cell lysates 
 
After the treatment with 25 or 50 µM of the gold compounds for 24 h, cells were washed in PBS 
and dissolved with 7.2M guanidine in a buffer containing 0.2M Tris-HCl, 5 mM EDTA, pH 8.1. 
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3 mM DTNB was then added to titrate the free thiol groups and the absorbance increase was 
monitored at 412 nm for 5 min.  
 
4.8 Total and oxidized glutathione estimation in cell lysates 
 
First, 5 × 105 2008 cells, were incubated for 48 h with 50 µM of 1 - 3. Then cells, washed twice 
with cold PBS, were rapidly lysed and deproteinized with 6% meta-phosphoric acid. After 10 
min at 4 °C, samples were centrifuged and supernatants were neutralized with 15% Na3PO4 and 
assayed for total glutathione, essentially as described in28  
To determine the amount of GSSG, aliquots (0.2 mL) of the obtained samples were derivatized 
with 2-vinylpyridine in order to block reduced glutathione, and oxidized glutathione was then 
estimated.29  
 
4.9 Redox Western blot analysis of Trx1 and Trx2  
 
The redox state of Trx1 and 2 was detected using a modified Western blot analysis30 utilizing 
the protocol describe in ref.31 Briefly, 2008 ovarian cancer cells incubated with the compounds 
for 48h, were lysed with 150 ȝL of urea lysis buffer (100 mM Tris-HCl, pH 8.3) containing 1 
mM EDTA, 8 M urea supplemented with 10 mM iodoacetamide (IAM) to derivatize free thiols. 
The incubation was carried out for 20 min at 37 °C. Subsequently, after the treatment with 3.5 
mM DTT for 30 min at 37 °C to reduce the oxidized thiols, cell lysates were derivatized with 
iodoacetic acid (IAA) (30 mM final concentration) for 30 min at 37 °C in order to  give a negative 
charge. Proteins (0.01 mg) were separated by urea-PAGE gel (7% acrylamide/bis(acrylamide) 
in 7 M urea) in non-reducing conditions and blotted using TurboSystem (Bio-Rad Laboratories, 
Hercules, CA, USA). Membranes were probed with the primary antibodies respectively for Trx1 
(FL 105) and for Trx2 (H75) (Santa Cruz Biotechnology, Santa Cruz, CA, USA).  
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